Please ensure Javascript is enabled for purposes of website accessibility

Is Moderna a Good Coronavirus Stock To Buy?

By Rachel Warren - Apr 15, 2020 at 7:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This biotech will soon start phase 2 trials of its coronavirus vaccine, marking some of the first human trials among all COVID-19 candidates.

As more biotech companies enter the mad race to get the first coronavirus vaccine from the testing lab to the market, Moderna (MRNA 3.27%) has placed itself at the front of the pack, with its most recent announcement that phase 2 trials for the company's vaccine candidate are imminent. On April 2, Moderna announced that the inaugural human trials for its coronavirus vaccine could move to phase 2 as soon as the end of spring or beginning of summer. Investors reacted accordingly, sending shares up by roughly 14% when the market closed that week from where they had started at the beginning of the week.

There's steep competition for investor dollars from companies like Inovio Pharmaceuticals (INO 6.08%), which just started human trials of its coronavirus vaccine last week, and Gilead Sciences (GILD 5.16%), which has already entered late-stage trials of its coronavirus drug candidate remdesivir in China. So you're not alone if you're unsure where you should be investing your hard-earned money in these uncertain times.

There are very few companies that have managed to ride out the sharp highs and lows of the coronavirus market thus far without experiencing significant losses, but Moderna is certainly one of them. Up by more than 60% since the beginning of 2020, Moderna shares have remained fairly buoyant, and the potential of a distributable vaccine looming in the offing has made this stock an increasingly attractive buy. 

Medical worker holding syringe

Image source: Getty Images

Phase 2 trials could begin before spring is out

Moderna's vaccine candidate, mRNA-1273, first began to garner attention in January when the U.S. National Institutes of Health (NIH) announced its plan to partner with the company in an early phase study of the prospective treatment. In early February, the first vials of the vaccine candidate were transferred from manufacturing to enter phase 1 testing.

By the middle of March, phase 1 trials had commenced with human test subjects in Washington State. At the daily coronavirus task force press briefing on April 1, Dr. Anthony Fauci, White House advisor and director of the National Institute of Allergy and Infectious Diseases, applauded the lightning-fast phase 1 launch and expressed his confidence that phase 2 was just a few months away.

In a timeline of its rapid response to the novel coronavirus and development of the vaccine candidate, Moderna stated:

Our mRNA platform provides significant advantages in speed and efficiency, across basic science, manufacturing, and clinical development. ...

For mRNA-1273, we were able to leverage our experience in vaccines to move rapidly on design and manufacture of material for the Phase 1 clinical trial. This included our broad understanding of the safety of our platform to date across more than 1,000 subjects. We also benefited from the use of our well-established manufacturing capabilities, which produced over 100 batches of mRNA medicines for use in human clinical trials in just the last two years.

In short, this isn't Moderna's first rodeo. The company is preparing for the next round of trials to begin as early as this spring and has already begun the manufacturing processes so it can hit the ground running if phase 2 gets the green light.

A riskier buy that could easily reap massive rewards

Even if phase 2 trials start before the end of spring, Moderna still anticipates that it could be a year to a year and a half before the vaccine is able to be administered to people in the general public. Moderna is currently trading at a price-to-sales ratio of approximately 180, as investors anticipate potentially massive rewards if and when mRNA-1273 hits the market.

Admittedly, Moderna is a buy that carries some risk, as do most coronavirus biotech stocks at this time. That being said, the company is definitively leading the race to develop a coronavirus vaccine with a well-established platform of mRNA manufacturing and design processes behind it. For this reason, Moderna is a viable buy for risk-tolerant investors.

Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$176.78 (3.27%) $5.60
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$66.21 (5.16%) $3.25
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$2.79 (6.08%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.